Who is this relevant for?
- Manufacturers evaluating UK market entry
- Distributors monitoring sourcing opportunities
Servier has completed its acquisition of Day One Biopharmaceuticals, closing a deal that gives it direct control of OJEMDA in the U.S. and adds a broader rare cancer pipeline to its oncology business.
The asset at the center of the transaction is OJEMDA, the brand name for tovorafenib, which Day One already markets in the United States for pediatric low-grade glioma. Servier said the acquisition strengthens its leadership in low-grade glioma and expands its oncology position through both a marketed product and clinical-stage assets in rare cancers.
That matters because this is not a pipeline-only acquisition. Servier is buying an FDA-approved medicine with an existing U.S. commercial footing, alongside a company built around targeted therapies in high-need oncology settings. For operators watching oncology portfolios, the move increases Servier’s weight in a focused rare cancer segment rather than broadening into an unrelated category.
What changes under Servier
With the tender offer completed, Day One will become a wholly owned subsidiary of Servier after the merger closes. Day One shares have already ceased trading on Nasdaq, and Servier said it intends to delist and deregister them.
From a commercialization standpoint, Servier now inherits a U.S. oncology product that is already on the market, plus the team and capabilities behind it. Servier also framed the deal as an expansion of its U.S. oncology presence, which suggests the acquisition is as much about execution capacity as it is about asset ownership.
Portfolio shape and territory split
The transaction also gives Servier a deeper oncology pipeline spanning early clinical development to Phase 3. Beyond tovorafenib, the company highlighted Emi-Le, an antibody drug conjugate, and DAY301, a targeted therapy in rare cancers.
One detail operators should note is the territorial structure around OJEMDA. Day One marketed the product in the U.S., but had already licensed rights outside the U.S. to Ipsen. That leaves Servier with control of the acquired business and product base in the U.S., while ex-U.S. rights remain tied to an existing licensing arrangement.
For companies tracking partnership structures in oncology, that split matters. It means the acquisition consolidates Servier’s position around the U.S. commercial asset and pipeline, without automatically bringing ex-U.S. commercialization in-house.
Why this stands out
Servier described the deal as part of its plan to strengthen its position in rare cancers, with a specific focus on pediatric low-grade glioma. Based on the release, the acquisition is tightly aligned to that objective: an approved U.S. product, additional development programs, and a business already operating in the same therapeutic area.
The total equity value of the transaction is about $2.5 billion, with Servier paying $21.50 per share in the tender offer. The deal is now complete from an ownership perspective, and the next phase will be about how Servier integrates Day One’s commercial, scientific, and clinical capabilities into its oncology operation.